Agorafobia

01Pathophysiology

Agoraphobia arises from a dysfunction in the brain's threat-detection and avoidance circuitry. The amygdala becomes hyperresponsive to environmental cues associated with perceived danger, such as crowded spaces, open areas, or situations where escape is perceived as difficult. This triggers an exaggerated autonomic fight-or-flight response mediated by the sympathetic nervous system, producing tachycardia, hyperventilation, sweating, and a subjective sense of impending doom.

The critical mechanism that sustains and worsens agoraphobia is negative reinforcement through avoidance. When a patient avoids a feared situation (e.g., a crowded market), the anxiety drops immediately. This relief powerfully reinforces the avoidance behavior, making the patient increasingly likely to avoid the same situation in the future. Over time, the range of avoided situations expands through a process of stimulus generalization: a patient who initially avoided only crowded malls may begin to avoid all public transportation, then all outdoor spaces, and eventually refuse to leave the house altogether.

This is why the PPDGJ-III criterion (c) emphasizes that avoidance must be a prominent feature of the presentation and that the patient may become "housebound". The avoidance is not a secondary behavior; it is the defining feature that distinguishes agoraphobia from simple anxiety episodes.

The prefrontal cortex, which normally provides top-down inhibitory regulation of the amygdala ("this situation is safe, the fear is excessive"), fails to adequately suppress the fear response. Cognitive-behavioral models describe this as catastrophic misinterpretation: the patient cognitively interprets benign physical sensations (mild tachycardia, dizziness) as evidence of a dangerous situation, which feeds back into the anxiety loop.

A key point for exam purposes: the PPDGJ-III requires that the psychological, behavioral, or autonomic symptoms must be the primary manifestation of anxiety and not secondary to other psychiatric symptoms such as delusions (waham) or obsessive thoughts (pikiran obsesif). This directly tests your ability to distinguish primary anxiety disorders from anxiety that occurs in the context of psychosis or OCD.

02Classification and Clinical Manifestation

PPDGJ-III Diagnostic Criteria (All Three Must Be Met)

Subtypes and Severity Spectrum

Agoraphobia With vs. Without Panic Disorder

03Diagnostic Workup

Agoraphobia is a clinical diagnosis. There is no laboratory test or imaging study that confirms it. The diagnostic workup serves two purposes: (1) to systematically verify that the patient meets PPDGJ-III criteria, and (2) to exclude medical conditions that mimic anxiety-related autonomic symptoms.

The best initial step when a patient presents with progressive avoidance of public places and anxiety symptoms is a thorough psychiatric interview. You are looking for three things: confirmation that the autonomic and psychological symptoms are the primary manifestation of anxiety (not secondary to psychosis or OCD), that the anxiety is situationally linked to at least two of the four listed scenarios, and that avoidance behavior is prominent.

After the clinical assessment, order a basic medical workup to rule out organic causes. Hyperthyroidism is the most important medical mimic, as it produces tachycardia, tremor, diaphoresis, and anxiety. Pheochromocytoma is rare but classically tested as a cause of episodic autonomic surges. Cardiac arrhythmias can present with palpitations and a sense of impending doom. Stimulant intoxication (cocaine, amphetamines) can produce acute panic-like episodes.

On an exam, if the vignette describes a patient with classic agoraphobic avoidance, normal vital signs between episodes, and no red flags (weight loss, exophthalmos, hypertension), the answer is clinical diagnosis based on criteria. Do not order unnecessary imaging.

04Management and Treatment

The most testable point in management is the combination of pharmacotherapy and psychotherapy. Neither alone is as effective as both together. On an exam, if the question asks for the single best initial treatment, the answer is typically SSRI plus CBT with exposure therapy.

Graded exposure is the cornerstone of CBT for agoraphobia. The therapist constructs a fear hierarchy with the patient (e.g., step 1: standing at the front door, step 2: walking to the end of the street, step 3: visiting a small shop, step 4: riding public transportation). The patient systematically works through these steps, learning through repeated experience that the feared catastrophe does not occur. This directly reverses the negative reinforcement cycle described in the pathophysiology section.

Benzodiazepines are a frequent exam trap. They provide rapid symptom relief, which makes them tempting as a first-line agent. However, they carry risks of dependence, tolerance, and rebound anxiety, and they interfere with the extinction learning that makes CBT effective. The correct use is short-term bridging only while waiting for the SSRI to reach therapeutic effect.

Contraindications and adjustments:

• In pregnancy, SSRIs (particularly sertraline) remain first-line as they have the most reassuring safety data. Benzodiazepines are avoided due to risks of neonatal sedation and withdrawal. Paroxetine is contraindicated in the first trimester due to cardiac teratogenicity.

• In elderly patients, start SSRIs at half the standard dose and titrate slowly. Benzodiazepines are particularly dangerous due to fall risk, cognitive impairment, and paradoxical agitation.

• In patients with comorbid substance use disorder, avoid benzodiazepines entirely. Emphasize CBT and SSRIs.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students lose points on agoraphobia questions is by confusing it with panic disorder or social phobia. Test-writers exploit this overlap deliberately. The distinguishing feature is always the pattern of avoidance: agoraphobia requires progressive avoidance of at least two situational categories (crowds, public places, leaving home, traveling alone) with the avoidance itself becoming a dominant, disabling symptom. If the vignette describes a patient who has panic attacks but continues to function in public without avoidance, the answer is panic disorder, not agoraphobia.

The second trap involves criterion (a) from PPDGJ-III. A vignette may describe a patient who avoids leaving the house, but the underlying reason is a paranoid delusion or obsessional fear of contamination. Students who focus only on the avoidance behavior and skip the requirement for primary anxiety will select agoraphobia incorrectly. Always ask: "Is the anxiety the primary driver, or is it secondary to another psychiatric process?"

The third common error is selecting benzodiazepines as first-line treatment. The vignette may emphasize the severity of the patient's distress, making rapid relief seem like the priority. The correct answer is always SSRI plus CBT. Benzodiazepines are acceptable only as a short-term bridge.

Finally, remember the PPDGJ-III "two-situation rule." If the patient's fear is limited to only one situation (e.g., only afraid of enclosed spaces), the diagnosis is a different phobia, not agoraphobia. The requirement for at least two of the four listed situations is a testable criterion that separates agoraphobia from other phobic disorders.